for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Transenterix Inc

TRXC.A

Latest Trade

0.37USD

Change

-0.00(-1.32%)

Volume

233,643

Today's Range

0.36

 - 

0.39

52 Week Range

0.28

 - 

10.40

As of on the NYSE MKT LLC ∙ Minimum 15 minute delay

Pricing

Previous Close
0.37
Open
0.39
Volume
233,643
3M AVG Volume
122.43
Today's High
0.39
Today's Low
0.36
52 Week High
10.40
52 Week Low
0.28
Shares Out (MIL)
99.88
Market Cap (MIL)
36.70
Forward P/E
-0.37
Dividend (Yield %)
--

Latest Developments

More

Transenterix, Inc. Reports Operating And Financial Results For The Second Quarter 2020

CVI Investments Inc Reports 8% Passive Stake In TransEnterix Inc

Empery Asset Management Reports 9.1% Passive Stake In Transenterix

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Transenterix Inc

TransEnterix, Inc. is a medical device company. The Company is focused on the development and commercialization of ALF-X Surgical Robotic System (the ALF-X System), and SurgiBot System. The Company's ALF-X System is a multi-port robotic surgery system, which allows multiple robotic arms to control instruments and a camera. The system features advanced technology to enable surgeons with haptic feedback and the ability to move the camera through eye movement. The system replicates laparoscopic motion and integrates three-dimensional high definition (3DHD) vision technology. The ALF-X System also offers responsible economics to hospitals by offering robotic technology with reusable instruments. The SurgiBot System is designed as a single-incision, patient-side robotic-assisted surgery system. The Company also develops and manufactures laparoscopic surgical instruments that are used in abdominal surgery, such as scissors, graspers, clip appliers, and suction and irrigation instruments.

Industry

Medical Equipment & Supplies

Contact Info

635 Davis Dr Ste 300

MORRISVILLE, NC

27560-7199

United States

+1.919.7658400

https://www.transenterix.com/

Executive Leadership

Paul A. LaViolette

Independent Chairman of the Board

Anthony C.J. Fernando

President, Chief Executive Officer, Director

Shameze Rampertab

Chief Financial Officer, Executive Vice President

Andrea Biffi

Independent Director

Jane H. Hsiao

Independent Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-12.610

2018

-3.120

2019

-4.220

2020(E)

-1.000
Price To Earnings (TTM)
--
Price To Sales (TTM)
9.25
Price To Book (MRQ)
0.35
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
4.73
LT Debt To Equity (MRQ)
4.73
Return on Investment (TTM)
-115.03
Return on Equity (TTM)
-101.62

Latest News

Latest News

BRIEF-CVI Investments Inc Reports 8% Passive Stake In TransEnterix Inc

* CVI INVESTMENTS INC REPORTS 8% PASSIVE STAKE IN TRANSENTERIX INC AS OF JULY 1- SEC FILING Source text: [ID:https://bit.ly/2VXuGpk] Further company coverage:

BRIEF-Empery Asset Management Reports 9.1% Passive Stake In Transenterix

* EMPERY ASSET MANAGEMENT LP REPORTS 9.1% PASSIVE STAKE IN TRANSENTERIX INC AS OF JULY 1 - SEC FILING Source text for Eikon: [ID: (https://bit.ly/2VV1uPO) Further company coverage:

BRIEF-TransEnterix Announces Pricing Of $13 Million Underwritten Public Offering Of Common Stock

* TRANSENTERIX ANNOUNCES PRICING OF $13.0 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK

BRIEF-Transenterix Announces Launch Of Underwritten Public Offering Of Common Stock

* TRANSENTERIX ANNOUNCES LAUNCH OF UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

BRIEF-Transenterix Inc - Sinai Health System In Chicago Has Entered Into An Agreement To Lease And Utilize A Senhance Surgical System

* TRANSENTERIX INC - SINAI HEALTH SYSTEM IN CHICAGO HAS ENTERED INTO AN AGREEMENT TO LEASE AND UTILIZE A SENHANCE SURGICAL SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Transenterix Reports Q4 Loss Per Share Of $0.69

* TRANSENTERIX, INC. REPORTS OPERATING AND FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2019

BRIEF-Transenterix Receives FDA Clearance For Machine Vision System In Robotic Surgery

* TRANSENTERIX RECEIVES FDA CLEARANCE FOR FIRST MACHINE VISION SYSTEM IN ROBOTIC SURGERY

BRIEF-Sabby Management LLC Reports 9.99% Passive Stake In Transenterix Inc

* SABBY MANAGEMENT LLC REPORTS 9.99% PASSIVE STAKE IN TRANSENTERIX INC AS OF MARCH 6, 2020 - SEC FILING Source text : (http://bit.ly/39w7P98) Further company coverage:

BRIEF-Transenterix Announces Launch Of Underwritten Public Offering

* TRANSENTERIX ANNOUNCES LAUNCH OF UNDERWRITTEN PUBLIC OFFERING

BRIEF-Transenterix Announces St. Marianna University School Of Medicine Toyoko Hospital In Japan

* TRANSENTERIX ANNOUNCES ST. MARIANNA UNIVERSITY SCHOOL OF MEDICINE TOYOKO HOSPITAL IN JAPAN TO INITIATE A SENHANCE DIGITAL LAPAROSCOPY PROGRAM Source text for Eikon: Further company coverage:

BRIEF-Transenterix Announces CE Mark Approval For Pediatric Indication For Senhance Surgical System

* TRANSENTERIX ANNOUNCES CE MARK APPROVAL FOR PEDIATRIC INDICATION FOR SENHANCE SURGICAL SYSTEM Source text for Eikon: Further company coverage:

BRIEF-Transenterix Has Entered Into Common Stock Purchase Agreement With Lincoln Park Capital Fund, Llc

* TRANSENTERIX - HAS ENTERED INTO COMMON STOCK PURCHASE AGREEMENT WITH LINCOLN PARK CAPITAL FUND, LLC

BRIEF-Transenterix Inc Files Prospectus Relates To Issuance Of Up To Additional 2.5 Million Shares Of Common Stock, Underlying Outstanding Series B Warrants

* TRANSENTERIX INC FILES PROSPECTUS RELATES TO ISSUANCE OF UP TO ADDITIONAL 2.5 MILLION SHARES OF COMMON STOCK, UNDERLYING OUTSTANDING SERIES B WARRANTS Source text: (https://bit.ly/2OC0VqK) Further company coverage:

BRIEF-Transenterix Inc Announces Loan Agreement With Hercules Capital

* TRANSENTERIX, INC. ANNOUNCES LOAN AGREEMENT WITH HERCULES CAPITAL

BRIEF-TransEnterix Reports Q1 Adjusted Loss Per Share $0.06

* TRANSENTERIX, INC. REPORTS OPERATING AND FINANCIAL RESULTS FOR THE FIRST QUARTER 2018

BRIEF-TransEnterix Reports Q4 Adjusted Loss Per Share $0.08

* TRANSENTERIX, INC. REPORTS OPERATING RESULTS FOR THE FOURTH QUARTER AND FULL YEAR 2017

BRIEF-TransEnterix says Florida hospital to purchase company's Senhance Surgical Robotic System​

* TransEnterix Inc - announced that Florida hospital entered into an agreement to purchase company's Senhance Surgical Robotic System Source text for Eikon: Further company coverage:

BRIEF-TransEnterix, Inc. reports results for the third quarter

* TransEnterix, Inc. Reports operating results for the third quarter 2017

Transenterix won't compete head-on with Intuitive Surgical: CEO

Transenterix Inc's chief executive played down on Tuesday the threat posed by his company's surgical robotic system to market leader Intuitive Surgical Inc, saying he did not expect the two to compete head on.

BRIEF-Transenterix announces US 510(K) FDA clearance for Senhance Surgical robotic system

* Transenterix announces US 510(K) FDA clearance for Senhance Surgical robotic system Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up